• 23andMe Offers 23andMe+

    Oct 27

    23andMe is offering current 23andMe health service customers in the U.S. 23andMe+, a new annual membership. This membership provides customers with exclusive access to genetic reports, as well as new reports and features as they become available throughout the year. Priced at $29/year, 23andMe+ will offer existing customers instant access t...


  • 23andMe Launched New Family Health History Tree

    Oct 15

    23andMe launched a new tool for their Health + Ancestry Service customers in the United States and Canada that can help people become more aware of their family's health history. It is called Family Health History Tree. 23andMe points out that many people are entirely unaware of their family's health history. Sometimes, knowledge doesn't ...


  • 23andMe Explains Your Privacy Protections

    Sep 22

    23andMe wants you to know that securing and protecting the your data is paramount. They are committed to keeping their customers' trust and providing a secure place where they can explore their DNA, knowing that their privacy is protected. There are three fundamental principals that 23andMe is guided by. The first is “Meaningful & Inf...


  • 23andMe Announced Insights from Lupus Research

    Sep 10

    23andMe collaborated with researchers from Pfizer to learn more about how to treat Lupus, a chronic autoimmune disease. The research was powered by almost 6,000 consented researcher participants. No new genetic associations were found, but 23andMe did uncover deeper insights into non-genetic factors and symptoms associated with the disease. ...


  • 23andMe Has Report on APOL1- Related Kidney Disease

    Aug 25

    23andMe added a new Genetic Health Risk report on APOL1-related chronic kidney disease. This disease has a particular relevance for 23andMe customers with African ancestry. The Chronic Kidney Disease (APOL1-Related) Genetic Health report includes two variants in the APOL1 gene that can increase the risk of developing chronic kidney diseas...


  • 23andMe and GSK Start Clinical Trial

    Aug 11

    23andMe has been collaborating with GlaskoSmithKline (GSK) for two years (as of July of 2020). The goal of the collaboration is to drive the discovery of novel, genetically validated drug targets to bring new transformational medicine to patients. Studies show that treatments that have been validated with genetic data are twice as likely to su...


  • 23andMe Improved its G6PD Deficiency Report

    Jul 14

    23andMe has updated its G6PD Deficiency Genetic Health Risk Report. The update includes testing for an additional variant linked to G6PD deficiency, a condition that can lead to episodes of anemia. Two of the most common variants linked to G6PD Deficiency are V68M and S188F. Previously, 23andMe reported on just one of those variants, V68M. ...


  • Study About Parkinson’s Includes Data from 23andMe

    Jun 9

    A new study about Parkinson's Disease, that was published in the journal Nature Medicine, relied on data from more than four million 23andMe customers. The results of the study may help speed efforts to find drug targets for treating Parkinson's disease. Working with researchers at 23andMe, scientists at the Broad Institute of MIT and Harva...


  • 23andMe Published a New BRCA Study

    May 12

    23andMe announced that their new BRCA study was published in Scientific Reports and is titled “Identifying Ashkenazi Jewish BRCA1/2 founder variants in individuals who do not self-report Jewish ancestry”. 23andMe says that this study could help inform the on-going discussion around broader access to BRCA genetic testing. The study is co...


  • 23andMe is Doing a Genetic Study on COVID-19

    Apr 23

    Beginning this week, 23andMe hopes to enroll hundreds of thousands of 23andMe customers in the United States to participate in a study about COVID-19. The study will include both individuals who have and have not tested positive for the virus. Scientists can quickly look for genetic variants that are more common among research participant...